The Australian market has had a strong start to the week, although the XJO remains significantly below its recent highs above 9,000 points. With materials leading the way and most sectors showing positive movement, investors are keeping a close eye on potential opportunities. Penny stocks, though considered somewhat of an outdated term, still represent an intriguing investment area as they often involve smaller or newer companies with potential for growth. In this article, we explore several penny stocks that could offer hidden value by combining solid financial foundations with long-term potential.
Top 10 Penny Stocks In Australia
| Name | Share Price | Market Cap | Rewards & Risks |
| Alfabs Australia (ASX:AAL) | A$0.465 | A$133.26M | ✅ 4 ⚠️ 3 View Analysis > |
| EZZ Life Science Holdings (ASX:EZZ) | A$2.19 | A$103.31M | ✅ 3 ⚠️ 2 View Analysis > |
| Dusk Group (ASX:DSK) | A$0.805 | A$50.13M | ✅ 4 ⚠️ 2 View Analysis > |
| IVE Group (ASX:IGL) | A$2.70 | A$417.04M | ✅ 4 ⚠️ 3 View Analysis > |
| MotorCycle Holdings (ASX:MTO) | A$3.41 | A$251.68M | ✅ 4 ⚠️ 2 View Analysis > |
| Pureprofile (ASX:PPL) | A$0.042 | A$49.13M | ✅ 3 ⚠️ 1 View Analysis > |
| Veris (ASX:VRS) | A$0.076 | A$39.35M | ✅ 4 ⚠️ 2 View Analysis > |
| West African Resources (ASX:WAF) | A$3.04 | A$3.47B | ✅ 4 ⚠️ 1 View Analysis > |
| Praemium (ASX:PPS) | A$0.75 | A$358.29M | ✅ 5 ⚠️ 2 View Analysis > |
| Service Stream (ASX:SSM) | A$2.32 | A$1.42B | ✅ 3 ⚠️ 1 View Analysis > |
Click here to see the full list of 425 stocks from our ASX Penny Stocks screener.
Let's explore several standout options from the results in the screener.
AMA Group (ASX:AMA)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: AMA Group Limited operates a collision repair business in Australia and New Zealand, with a market cap of A$445.07 million.
Operations: The company's revenue is primarily derived from its Ama Collision segment at A$360.04 million and Capital Smart at A$490.33 million, supplemented by ACM Parts with A$99.70 million, Wales contributing A$77.88 million, and Specialist Businesses adding A$56.29 million.
Market Cap: A$445.07M
AMA Group Limited, with a market cap of A$445.07 million, reported annual sales of A$1.01 billion for the year ending June 30, 2025. Though unprofitable with a net loss of A$7.47 million, the company has reduced its losses over the past five years by approximately 21% annually and maintains a cash runway exceeding three years if it continues its current free cash flow trends. Trading at nearly half its estimated fair value and showing no significant shareholder dilution recently, AMA's debt-to-equity ratio has improved significantly over five years from 112.4% to 31.9%.
- Jump into the full analysis health report here for a deeper understanding of AMA Group.
- Examine AMA Group's earnings growth report to understand how analysts expect it to perform.
IVE Group (ASX:IGL)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: IVE Group Limited, along with its subsidiaries, operates in the marketing sector in Australia and has a market capitalization of A$417.04 million.
Operations: The company generates revenue from its Advertising segment, which amounts to A$959.25 million.
Market Cap: A$417.04M
IVE Group Limited, with a market cap of A$417.04 million, reported significant revenue of A$959.25 million for the year ending June 30, 2025. The company has shown robust earnings growth of 69.2% over the past year and maintains high-quality earnings with improved net profit margins at 4.9%. Its seasoned management team and board contribute to its strategic direction as it seeks acquisitions in creative sectors. Although IVE's debt levels are high, its debt is well covered by operating cash flow (67.1%). The recent share buyback reflects confidence in its financial health despite an unstable dividend track record.
- Navigate through the intricacies of IVE Group with our comprehensive balance sheet health report here.
- Explore IVE Group's analyst forecasts in our growth report.
Starpharma Holdings (ASX:SPL)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Starpharma Holdings Limited is a biopharmaceutical company focused on the research, development, and commercialization of dendrimer technology for pharmaceutical and healthcare applications globally, with a market cap of A$94.10 million.
Operations: The company's revenue is primarily derived from the discovery, development, and commercialization of dendrimers, generating A$5.85 million.
Market Cap: A$94.1M
Starpharma Holdings Limited, with a market cap of A$94.10 million, is focused on dendrimer technology but remains pre-revenue with sales of A$4.91 million for the year ending June 30, 2025. The company reported a net loss of A$9.99 million and maintains a negative return on equity at -52.58%. Despite being unprofitable, Starpharma has reduced losses over the past five years by 14% annually and holds more cash than debt, ensuring a cash runway exceeding two years if current free cash flow growth persists. However, its share price has been highly volatile recently and management lacks extensive tenure experience.
- Get an in-depth perspective on Starpharma Holdings' performance by reading our balance sheet health report here.
- Evaluate Starpharma Holdings' historical performance by accessing our past performance report.
Where To Now?
- Navigate through the entire inventory of 425 ASX Penny Stocks here.
- Ready To Venture Into Other Investment Styles? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if IVE Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com